CD40LG and myeloid sarcoma: After 6 months of teriflunomide treatment, antiviral antibody titers decreased in 61/101 (60.4%) MS patients for HHV-6 IgG, 75/101 (74.3%) for HHV-6 IgM, 74/101 (73.3%) for EBNA-1 IgG and 69/100 (69%) for VCA IgG (Figure 2).